- Home
- SIGA vs OABI Comparison
SIGA vs OABI Comparison
Compare SIGA & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIGA | OABI |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.0M | 241.8M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SIGA | OABI |
|---|---|---|
| Price | $5.25 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 666.7K | 268.4K |
| Earning Date | 03-10-2026 | 03-04-2026 |
| Dividend Yield | ★ 12.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | $224.81 | $64.69 |
| P/E Ratio | $15.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.81 | $1.22 |
| 52 Week High | $9.62 | $2.43 |
Technical Indicators
Market Signals| Indicator | SIGA | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 29.76 |
| Support Level | $4.81 | $1.27 |
| Resistance Level | $6.98 | $1.75 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 52.91 | 4.42 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.